<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200504047299N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-08</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>comparison of the effect of cinnamon and vitex oral capsules on sexual function in postmenopausal women</public_title>
      <acronym></acronym>
      <scientific_title>comparison of the effect of cinnamon and vitex oral capsules on sexual function in postmenopausal women coverd by selected health centers affiliated to shahid beheshti university of medical sciences in 2019</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-01-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>105</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47716</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random numbers were used to randomize and assign individuals to groups; randomization using Excel software is as follows:
First, in a column, groups are entered as A, B, c, and below, because the number of samples in each group is set to 35 (including the sample fall), so 35, B, A c must be as follows. And they come in regularly. In the opposite column, random numbers are generated using the RAND command. In the next step, using the sort command, random numbers generated from small to large or vice versa are arranged, which causes the order of the groups, c, A, B, to change. Using the new order, people are assigned to different groups, Blinding description: This study is a randomized triple-blind clinical trial, meaning that the researcher, research sample, and statistical consultant professor are unaware of what drugs each group is taking, or which of the A, B or C envelopes contain which drugs.</study_design>
      <phase>3</phase>
      <hc_freetext>اختلال کارکرد جنسی.</hc_freetext>
      <i_freetext>Intervention 1: The  intervention group is menopausal women, which will be divided into two groups: oral cinnamon capsules (400 mg) and vitex-agnus capsules (400 mg). The capsules will be provided at the School of Pharmacy of Shahid Beheshti University of Medical Sciences, and postmenopausal women will take 2 capsules a day for 2 months. Intervention 2: The control group is menopausal women who will receive placebo capsules. These capsules were prepared in the Faculty of Pharmacy in Shahid Beheshti University of Medical Sciences and were matched with cinnamon capsules and vitex-agnus in terms of appearance. Samples take 2 of these capsules for 2 months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the consequences will be shared

When:
3 month after outcomes

To whom:
Researchers working in academic and scientific institutions

Conditions:
In order to perform more accurate clinical trials

Where to obtain:
Nursing and Midwifery Faculty of Shahid beheshti university of medical science

How to obtain:
It will be available as soon as possible after requesting information

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tanya Koliji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 58., Raees zade Ave., Tehran villa St., Satarkhan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1444734779</zip>
        <telephone>+98 21 6652 0143</telephone>
        <email>tanipaezan.koliji@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elham Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 58., Raees zade Ave., Tehran Villa St., Satarkhan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۴۴۷۳۷۷۹</zip>
        <telephone>+98 21 6652 0143</telephone>
        <email>elhamzare.phd@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Be Iranian.
2. Have at least literacy.
3. Do not have speech, hearing or mental disorders that prevent communication with the researcher.
4. It's been at least a year since they stopped menstruating.
5. Have a married life with her spouse.
6. There is no inclination or obligation to use hormone replacement therapy.
7. As menopausal woman sated, do not use any chemical or herbal remedies to treat her problem.
8. Have sexual activity.
9. A postmenopausal wife does not have a sexual problem.
10. They have not undergone hysterectomy and ovariectomy, cystocele, rectocele, and mastectomy.
11. Menopausal women and their spouses do not have a known mental illness.
12. Not addicted to cigarettes or drugs.
13. He has not recently used antidepressants drugs.
14. Have no history of known chronic diseases such as high blood pressure, diabetes, asthma, weaken the immune system, etc.
15. Has no history of allergy to medicinal plants.
16. Do not use herbal teas during medication.
17. Age between 45 and 65 years</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>1. Possible sensitivity to capsules
2. Do not take the capsule for a week or more
3. Lack of desire to continue treatment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sexual dysfunction not due to a substance or known physiological condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The  intervention group is menopausal women, which will be divided into two groups: oral cinnamon capsules (400 mg) and vitex-agnus capsules (400 mg). The capsules will be provided at the School of Pharmacy of Shahid Beheshti University of Medical Sciences, and postmenopausal women will take 2 capsules a day for 2 months.</i_keyword>
      <i_keyword>The control group is menopausal women who will receive placebo capsules. These capsules were prepared in the Faculty of Pharmacy in Shahid Beheshti University of Medical Sciences and were matched with cinnamon capsules and vitex-agnus in terms of appearance. Samples take 2 of these capsules for 2 months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sexual dysfunction according to the FSFI questionnaire. Timepoint: Before intervention, 2 month after intervention, 3 month after intervention. Method of measurement: FSFI questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sexual desire. Timepoint: Before intervention, 2 month after intervention, 3 moth after intervention. Method of measurement: The Female Sexual Function Index (FSFI) questionnaire.</sec_outcome>
      <sec_outcome>Sexual satisfaction. Timepoint: Before intervention, 2 month after intervention, 3 month after intervention. Method of measurement: The Female Sexual Function Index (FSFI) questionnaire.</sec_outcome>
      <sec_outcome>Orgasm. Timepoint: Before intervention, 2 month after intervention, 3 month after intervention. Method of measurement: The Female Sexual Function Index (FSFI) questionnaire.</sec_outcome>
      <sec_outcome>Arousal. Timepoint: Before intervention, 2 month after intervention, 3 month after intervention. Method of measurement: The Female Sexual Function Index (FSFI) questionnaire.</sec_outcome>
      <sec_outcome>Lubrication. Timepoint: Before intervention, 2 month after intervention, 3 month after intervention. Method of measurement: The Female Sexual Function Index (FSFI) questionnaire.</sec_outcome>
      <sec_outcome>Pain during intercourse. Timepoint: Before intervention, 2 month after intervention, 3 month after intervention. Method of measurement: The Female Sexual Function Index (FSFI) questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-10</approval_date>
        <contact_name>Ethics committee of shahid beheshti university of medical science</contact_name>
        <contact_address>No. 58, Raees zadeh St., Tehran villa Ave., Satarkhan14 tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
